About this FactMed analysis covering adverse side effect reports of ALBUMINAR-25 patients who developed HAEMOLYSIS.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 1 individuals taking ALBUMINAR-25 reported HAEMOLYSIS to the FDA. A total of 49 ALBUMINAR-25 drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between ALBUMINAR-25 and HAEMOLYSIS. In doing so, we compare ALBUMINAR-25 with other drugs that cause HAEMOLYSIS, to help you evaluate whether or not ALBUMINAR-25 causes HAEMOLYSIS. Likewise, this page shows the most highly-reported side effects of ALBUMINAR-25, so you can see if HAEMOLYSIS ranks among ALBUMINAR-25's most well-known side effects.
Summary Statistics
Reports of ALBUMINAR-25 causing HAEMOLYSIS: 1
Reports of any side effect of ALBUMINAR-25 : 49
Percentage of ALBUMINAR-25 patients where HAEMOLYSIS is a reported side effect: 2.0408%

FDA reports of any drug causing HAEMOLYSIS : 2798
Average percentage for all medicated patients where HAEMOLYSIS is reported as a complication: 0.0175%

Physician opinion on ALBUMINAR-25 as adverse event culprit:

Overall opinion for all reports of this drug:
Most frequent diagnoses/indications for prescribing ALBUMINAR-25:
PRODUCT USED FOR UNKNOWN INDICATION ( 9 patients )
HYPOALBUMINAEMIA ( 6 patients )
CARDIAC FAILURE ( 2 patients )
SURGERY ( 2 patients )
DRUG USE FOR UNKNOWN INDICATION ( 2 patients )
HAEMODYNAMIC INSTABILITY ( 2 patients )
METASTASES TO LYMPH NODES ( 2 patients )
NEPHROTIC SYNDROME ( 2 patients )
RENAL FAILURE ACUTE ( 2 patients )
URINE OUTPUT DECREASED ( 2 patients )
HEPATIC CIRRHOSIS ( 2 patients )
HYPOTENSION ( 2 patients )
MYASTHENIA GRAVIS ( 1 patients )
PLASMAPHERESIS ( 1 patients )
LIVER DISORDER ( 1 patients )
PNEUMONIA ( 1 patients )
ASCITES ( 1 patients )
CENTRAL VENOUS PRESSURE DECREASED ( 1 patients )
GENERALISED OEDEMA ( 1 patients )
LYMPHANGIOMA ( 1 patients )
( 0 patients )
Drugs with high FDA adverse event association with HAEMOLYSIS:

SOLIRIS (1600 patients)
GAMUNEX (247 patients)
FOLIC ACID (191 patients)
GAMMAGARD LIQUID (178 patients)
PREDNISONE (153 patients)
ASPIRIN (148 patients)
HEPARIN SODIUM INJECTION (132 patients)
EXJADE (122 patients)
CYCLOSPORINE (108 patients)
ACETAMINOPHEN (105 patients)
WINRHO SDF (103 patients)
PLATELETS (99 patients)
LASIX (96 patients)
PREDNISOLONE (87 patients)
WINRHO (82 patients)
OMEPRAZOLE (81 patients)
CYCLOPHOSPHAMIDE (80 patients)
PRIVIGEN (77 patients)
COUMADIN (75 patients)
PLATELETS A POSITIVE (PLATELETS, HUMAN BLOOD) (74 patients)
ARANESP (72 patients)
WARFARIN SODIUM (71 patients)
CEFTRIAXONE (69 patients)
ALLOPURINOL (67 patients)
POTASSIUM CHLORIDE (62 patients)
RIBAVIRIN (61 patients)
NEXIUM (60 patients)
PROGRAF (60 patients)
FLUOROURACIL (60 patients)
PREDNISONE TAB (59 patients)
LOVENOX (58 patients)
RED BLOOD CELLS (57 patients)
TACROLIMUS (52 patients)
INSULIN (52 patients)
FUROSEMIDE (52 patients)
LISINOPRIL (51 patients)
VANCOMYCIN (51 patients)
WINRHO SDF LIQUID (50 patients)
LEVOTHYROXINE SODIUM (49 patients)
METHOTREXATE (47 patients)
DEXAMETHASONE (46 patients)
RITUXIMAB (45 patients)
SOLU-MEDROL (44 patients)
SIMVASTATIN (44 patients)
NEORAL (44 patients)
IBUPROFEN (43 patients)
IMMUNE GLOBULIN INTRAVENOUS (HUMAN) (42 patients)
BENADRYL (41 patients)
PROPOFOL (41 patients)
DIGOXIN (41 patients)
LIPITOR (41 patients)
FLUCONAZOLE (40 patients)
ACYCLOVIR (40 patients)
PLAVIX (40 patients)
NORVASC (40 patients)
OXALIPLATIN (39 patients)
NPLATE (39 patients)
THYMOGLOBULIN (39 patients)
SYNTHROID (38 patients)
MORPHINE (38 patients)
FENTANYL (37 patients)
CALCIUM (37 patients)
HYDROCHLOROTHIAZIDE (36 patients)
AMLODIPINE (36 patients)
HEPARIN (35 patients)
ZOFRAN (35 patients)
MYCOPHENOLATE MOFETIL (35 patients)
SUTENT (34 patients)
PANTOPRAZOLE (34 patients)
METHYLPREDNISOLONE (34 patients)
AMBIEN (34 patients)
CELLCEPT (33 patients)
ZANTAC (33 patients)
PEGASYS (33 patients)
LANSOPRAZOLE (32 patients)
NEUPOGEN (32 patients)
ROCEPHIN (32 patients)
REVLIMID (32 patients)
CALCIUM CARBONATE (30 patients)
AUGMENTIN '125' (30 patients)
SPIRONOLACTONE (30 patients)
FAMOTIDINE (30 patients)
ZOCOR (30 patients)
CARBOPLATIN (29 patients)
LORAZEPAM (29 patients)
VIOXX (28 patients)
ALBUTEROL (28 patients)
CIPROFLOXACIN (28 patients)
ALPRAZOLAM (28 patients)
DIOVAN (28 patients)
BACTRIM (28 patients)
FRAGMIN (28 patients)
AVASTIN (27 patients)
ATENOLOL (27 patients)
NIFEDIPINE (27 patients)
FLUDARA (27 patients)
ALDACTONE (27 patients)
GEMZAR (27 patients)
MULTI-VITAMINS (26 patients)
VITAMIN D (26 patients)
FERROUS SULFATE TAB (26 patients)
ATIVAN (26 patients)
MABTHERA (26 patients)
ZOLOFT (26 patients)
PROCRIT (25 patients)
RANITIDINE (25 patients)
TYLENOL (CAPLET) (25 patients)
METOPROLOL SUCCINATE (25 patients)
METOPROLOL TARTRATE (25 patients)
CRESTOR (25 patients)
FLUDARABINE PHOSPHATE (24 patients)
LEVAQUIN (24 patients)
CYTARABINE (24 patients)
PLATELETS A POSITIVE (PLATELETS, HUMAND BLOOD) (24 patients)
EPOGEN (24 patients)
TORSEMIDE (24 patients)
MAGNESIUM OXIDE (24 patients)
AMBISOME (24 patients)
CAMPATH (24 patients)
ETOPOSIDE (23 patients)
RAMIPRIL (23 patients)
PROTONIX (23 patients)
DECADRON (23 patients)
IRON (23 patients)
URSODIOL (23 patients)
TOPROL-XL (23 patients)
PRILOSEC (22 patients)
SANDIMMUNE (22 patients)
RAPAMUNE (22 patients)
GLEEVEC (22 patients)
VESICARE (22 patients)
XELODA (22 patients)
LEUCOVORIN CALCIUM (22 patients)
CORDARONE (22 patients)
LANTUS (21 patients)
DILAUDID (21 patients)
HEPARIN SODIUM (21 patients)
TYLENOL (20 patients)
MECLIZINE (20 patients)
LOPERAMIDE (20 patients)
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% (20 patients)
GLYBURIDE (20 patients)
NITROGLYCERIN (20 patients)
CISPLATIN (20 patients)
PERCOCET (20 patients)
HUMAN RED BLOOD CELLS A1 POSITIVE (HUMAN RED BLOOD CELLS) (20 patients)
XANAX (20 patients)
VELCADE (20 patients)
VIDAZA (20 patients)
PANTOPRAZOLE SODIUM (20 patients)
LEVOFLOXACIN (20 patients)
CELEXA (20 patients)
LEXAPRO (19 patients)
GLUCOPHAGE (19 patients)
ENALAPRIL MALEATE (19 patients)
BUMEX (19 patients)
VINCRISTINE (19 patients)
CAPTOPRIL (19 patients)
BEVACIZUMAB (19 patients)
DAPSONE (19 patients)
LACTULOSE (19 patients)
COREG (19 patients)
ISOSORBIDE MONONITRATE (18 patients)
MILRINONE (18 patients)
PEGINTERFERON ALFA-2A (18 patients)
VITAMIN B-12 (18 patients)
AZITHROMYCIN (18 patients)
REBETOL (18 patients)
CARVEDILOL (18 patients)
MULTI-VITAMIN (18 patients)
VOLTAREN (18 patients)
NOVOLIN 70/30 (18 patients)
ZITHROMAX (18 patients)
METFORMIN HCL (18 patients)
SINGULAIR (18 patients)
PEPCID (18 patients)
FLUDARABINE (18 patients)
PREVACID (17 patients)
HYDROCORTISONE (17 patients)
PREVISCAN (17 patients)
ACTOS (17 patients)
PHENERGAN HCL (17 patients)
ALTACE (17 patients)
AMARYL (17 patients)
AMINOPYRIDINE (17 patients)
VASOTEC (17 patients)
KEPPRA (17 patients)
PEG-INTRON (17 patients)
SODIUM BICARBONATE (17 patients)
IRON SULFATETHIAMIN COMPOUND TAB (17 patients)
VICODIN (16 patients)
MEROPENEM (16 patients)
RED BLOOD CELLS, CONCENTRATED (16 patients)
GANCICLOVIR (16 patients)
REGLAN (16 patients)
CLOPIDOGREL (16 patients)
ZETIA (16 patients)
METOCLOPRAMIDE (16 patients)
METOPROLOL (16 patients)
NORVIR (16 patients)
PROMETHAZINE (16 patients)
METHYLPREDNISOLONE 16MG TAB (16 patients)
ATARAX (16 patients)
AMLODIPINE BESYLATE (16 patients)
AMOXICILLIN (16 patients)
DOPAMINE HCL (15 patients)
VINCRISTINE SULFATE (15 patients)
FOSAMAX (15 patients)
RENAGEL (15 patients)
ELOXATIN (15 patients)
Most common side effects for patients taking ALBUMINAR-25:
BLOOD PRESSURE DECREASED (11 patients)
INFUSION RELATED REACTION (7 patients)
HEPATITIS C POSITIVE (4 patients)
OXYGEN SATURATION DECREASED (4 patients)
HEPATIC FAILURE (3 patients)
HEPATITIS C ANTIBODY POSITIVE (3 patients)
TACHYCARDIA (3 patients)
HEPATITIS C VIRUS TEST POSITIVE (3 patients)
ANTINUCLEAR ANTIBODY POSITIVE (3 patients)
PYREXIA (3 patients)
HYPERSENSITIVITY (3 patients)
CHILLS (3 patients)
BLOOD CULTURE POSITIVE (2 patients)
PLATELET COUNT DECREASED (2 patients)
LOSS OF CONSCIOUSNESS (2 patients)
PRODUCT QUALITY ISSUE (2 patients)
KLEBSIELLA INFECTION (2 patients)
BACTERIAL INFECTION (2 patients)
BODY TEMPERATURE INCREASED (2 patients)
HYPOXIA (2 patients)
HYPOTENSION (2 patients)
PRURITUS (2 patients)
PULMONARY EMBOLISM (2 patients)
RASH (2 patients)
HEPATITIS C RNA POSITIVE (2 patients)
CROHN'S DISEASE (2 patients)
RESTLESSNESS (2 patients)
TRANSMISSION OF AN INFECTIOUS AGENT VIA A MEDICINAL PRODUCT (2 patients)
HEPATITIS B VIRUS TEST POSITIVE (2 patients)
HEPATITIS B POSITIVE (2 patients)
DYSKINESIA (2 patients)
HEPATITIS (2 patients)
HEPATITIS C (2 patients)
HEADACHE (2 patients)
FOAMING AT MOUTH (2 patients)
FLUSHING (2 patients)
FATIGUE (1 patients)
HAEMOGLOBIN DECREASED (1 patients)
HAEMOLYSIS (1 patients)
EYE SWELLING (1 patients)
ENTEROCOLONIC FISTULA (1 patients)
HEPATIC FUNCTION ABNORMAL (1 patients)
DYSPNOEA (1 patients)
HEPATITIS B CORE ANTIGEN POSITIVE (1 patients)
DRUG HYPERSENSITIVITY (1 patients)
HEPATITIS B SURFACE ANTIGEN POSITIVE (1 patients)
DIARRHOEA (1 patients)
ABDOMINAL DISCOMFORT (1 patients)
CYANOSIS (1 patients)
CULTURE URINE POSITIVE (1 patients)
CORONARY ARTERY INSUFFICIENCY (1 patients)
COOMBS DIRECT TEST POSITIVE (1 patients)
COMPLICATIONS OF TRANSPLANTED LIVER (1 patients)
CATHETER SITE HAEMORRHAGE (1 patients)
CARDIO-RESPIRATORY ARREST (1 patients)
BLOOD PRESSURE SYSTOLIC DECREASED (1 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (1 patients)
BLOOD PRESSURE FLUCTUATION (1 patients)
LABORATORY TEST ABNORMAL (1 patients)
LARGE INTESTINE PERFORATION (1 patients)
LIP SWELLING (1 patients)
LIVER TRANSPLANT (1 patients)
BLOOD GLUCOSE INCREASED (1 patients)
NEUTROPHIL COUNT DECREASED (1 patients)
NOSOCOMIAL INFECTION (1 patients)
ORTHOPNOEA (1 patients)
BLOOD FIBRINOGEN DECREASED (1 patients)
PALLOR (1 patients)
BLOOD CREATININE INCREASED (1 patients)
PNEUMONIA KLEBSIELLA (1 patients)
POST PROCEDURAL COMPLICATION (1 patients)
PRODUCT OUTER PACKAGING ISSUE (1 patients)
PRODUCT PACKAGING QUANTITY ISSUE (1 patients)
BLOOD BILIRUBIN INCREASED (1 patients)
PROTHROMBIN TIME PROLONGED (1 patients)
BACK PAIN (1 patients)
ASTHENIA (1 patients)
PULMONARY OEDEMA (1 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (1 patients)
ANAPHYLACTIC SHOCK (1 patients)
RECTAL HAEMORRHAGE (1 patients)
RENAL DISORDER (1 patients)
ANAPHYLACTIC REACTION (1 patients)
RETROPERITONEAL ABSCESS (1 patients)
SEROLOGY POSITIVE (1 patients)
SWELLING FACE (1 patients)
ALANINE AMINOTRANSFERASE INCREASED (1 patients)
ADVERSE EVENT (1 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (1 patients)
URINARY TRACT INFECTION FUNGAL (1 patients)
URINE OUTPUT DECREASED (1 patients)
URTICARIA (1 patients)
VENA CAVA THROMBOSIS (1 patients)
WHITE BLOOD CELL COUNT DECREASED (1 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.


Recent FactMed Activity for ALBUMINAR-25


Issue Description / Topic Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about HAEMOLYSIS and ALBUMINAR-25, post it here. You may receive a response from a fellow patient - or a leading expert in the field.
Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking ALBUMINAR-25, post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.
Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in ALBUMINAR-25. This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.
We are currently accepting registration for ALBUMINAR-25 experts. If you are a healthcare provider experienced in prescribing ALBUMINAR-25, please register here.
giCould not connect: